Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
6.97
-0.43 (-5.81%)
At close: Jun 26, 2026, 4:00 PM EDT
7.11
+0.14 (2.01%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Company Description
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.
The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Sanjeev Luther |
Contact Details
Address: 1035 Cambridge Street, Suite 18A Cambridge, Massachusetts 02141 United States | |
| Phone | 617 798 6700 |
| Website | ernexatx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082407 |
| ISIN Number | US1140824079 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President and Director |
| Sandra M. Gurrola | Senior Vice President of Finance |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Dorothy J. Clarke | General Counsel |
| Dr. Kanika Chawla Ph.D. | Senior Vice President of Technical Operations (Consultant) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 8-K | Current Report |
| May 20, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | SCHEDULE 13G | Filing |
| May 14, 2026 | SCHEDULE 13G | Filing |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | ARS | Filing |
| May 11, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 11, 2026 | DEF 14A | Other definitive proxy statements |